Sanara Medtech Inc SMTI.OQ reported a quarterly adjusted loss of 18 cents per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of two analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -19 cents to -4 cents per share.
Revenue rose 48.7% to $26.31 million from a year ago; analysts expected $25.80 million.
Sanara Medtech Inc's reported EPS for the quarter was a loss of 18 cents.
The company reported a quarterly loss of $1.54 million.
Sanara Medtech Inc shares had risen by 7.5% this quarter.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 65.2% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Sanara Medtech Inc is $48.00
This summary was machine generated from LSEG data March 25 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Dec. 31 2024 | -0.11 | -0.18 | Missed |
Sep. 30 2024 | -0.62 | -0.34 | Beat |
Jun. 30 2024 | -0.21 | -0.41 | Missed |
Mar. 31 2024 | -0.07 | -0.21 | Missed |
Comments